Patent ID: 9115398
Filing Date: 2015-08-25
Classification: A61K,A61P,C12Q

Abstract:
1. A method for determining the prognosis of a clinical response to a central nervous system (CNS)-active medicament which is a substrate of the ABCB1 protein and treating a human patient suffering from depressive disorder, dysthymia and/or bipolar disorder, comprising (a) determining the presence of a C allele of polymorphism rs4148740 using genotyping analysis in a human patient suffering from depressive disorder, dysthymia and/or bipolar disorder, wherein said genotyping analysis allows a discrimination between polymorphism rs4148740 and other polymorphisms, wherein said genotyping analysis allows a discrimination between the T allele and the C allele of said polymorphism rs4148740, and wherein the genotyping analysis comprises the use of polymorphism-specific primers; (b) selecting a patient where the C allele of said polymorphism rs4148740 is present, wherein the presence of said C allele of the polymorphism in the ABCB1 gene of said patient indicates an improved response to a central nervous system (CNS)-active medicament which is a substrate of the ABCB1 protein as compared to patients where the T allele is present; and (c) administering an antidepressant which is an ABCB1 substrate to said patient.